Strategic partnerships ALigos is actively engaging in exclusive license agreements and research collaborations (HBV, pevifoscorvir, and collaborations with Amoytop) signaling openness to partnerships that expand geographic reach and accelerate product development, presenting opportunities for BD teams to propose co-development, licensing, or regional commercialization deals.

Global licensing Recent China rights sale for the HBV program demonstrates strong appetite for regional licensing and monetization of mature assets, suggesting BD opportunities to structure regional licenses, milestones, and royalty streams in high-potential markets.

Revenue diversification License revenue contributed to quarterly results with a modest bottom-line impact, while the company maintains a clinical-stage profile with a substantial funding runway, indicating sales plays around licensing, collaboration upfronts, and milestone-driven partnerships to de-risk commercialization.

Focused therapeutic focus Strong emphasis on liver and viral diseases, including HBV and MASH, creates targeted selling points for public-sector grants, contract research, and alliance opportunities with specialty pharma, CROs, and biotech manufacturers seeking to bolster antiviral and hepatology portfolios.

Strategic leadership Key personnel changes and leadership in business development (previous VP appointments) signal a proactive BD function, providing entry points for executive-level discussions on alliances, joint ventures, or strategic investments aligned with long‑term pipeline milestones.